GlassScriptPhysician profile
Joseph Gutman
NPI 1780633875
$4,357.32
in general payments reported to CMS, 2019-2025
21 companies · $57.85 in 2025
The $57.85 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $3,556 · 2022: $86.83 · 2023: $190 · 2024: $310 · 2025: $57.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542 · Education: $16.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.55 |
| Education | $16.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,643.69 | 2019-2023 | Rybelsus, Ozempic |
| Lundbeck LLC | $95.33 | 2024 | Rexulti |
| Boston Scientific Corporation | $91.97 | 2023-2024 | |
| Insulet Corporation | $49.80 | 2023 | Omnipod |
| Merck Sharp & Dohme LLC | $49.31 | 2020-2023 | Januvia, Belsomra |
| Abbott Laboratories | $44.99 | 2022-2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $43.63 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $41.93 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.99 | 2020 | |
| Lilly USA, LLC | $31.09 | 2022-2023 | Jardiance |
| Abbvie INC. | $29.47 | 2024 | |
| Amgen INC. | $27.17 | 2020-2024 | Evenity, Prolia |
| Cequr Corporation | $21.09 | 2024 | Cequr Simplicity |
| Medtronic, INC. | $21.01 | 2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $20.51 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.09 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2023 | Entyvio |
| Bayer Healthcare Pharmaceuticals INC. | $18.27 | 2024 | |
| Pfizer INC. | $17.55 | 2020 | |
| Corcept Therapeutics | $16.75 | 2025 | Korlym |
| Radius Health, INC. | $16.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.